Advancing the global public health agenda for NAFLD: a consensus statement

Nature Reviews Gastroenterology and Hepatology - Tập 19 Số 1 - Trang 60-78 - 2022
Jeffrey V. Lazarus1, Henry E. Mark2, Quentin M. Anstee3, Juan Pablo Arab4, Rachel L. Batterham5, Laurent Castéra6, Helena Cortez‐Pinto7, Javier Crespo8, Kenneth Cusi9, M. Ashworth Dirac10, Sven Francque11, Jacob George12, Hannes Hagström13, Terry T.‐K. Huang14, Mona Ismail15, Achim Kautz16, Shiv Kumar Sarin17, Rohit Loomba18, Veronica Miller19, Philip N. Newsome20, Michael Ninburg21, Ponsiano Ocama22, Vlad Ratziu23, Mary E. Rinella24, Diana Romero25, Manuel Romero‐Gómez26, Jörn M. Schattenberg27, Emmanuel Tsochatzis28, Luca Valenti29, Vincent Wai‐Sun Wong30, Yusuf Yılmaz31, Zobair M. Younossi32, Shira Zelber‐Sagi33, Fredrik Åberg34, Leon A. Adams35, Maryam Salem Al Khatry36, Khalid Al Naamani37, Omar Alfaro Murillo38, Alina M. Allen39, Faisal Abdullatif Alnaser40, Saleh A. Alqahtani41, Khalid Alswat42, Domenico Alvaro43, Raúl J. Andrade44, Marco Arrese4, Yaw Asante Awuku45, Motala Ayesha46, Oidov Baatarkhuu47, Shokhista Bakieva48, Rita Basu49, Ramón Bataller50, Shahinaz Bedri51, Emanuele Bosi52, Marc Bourlière53, Radan Brůha54, Elisabetta Bugianesi55, Patrizia Burra56, Marı́a Buti57, Christopher D. Byrne58, José Luís Calleja59, Patrizia Carrieri60, Flloyd Carter61, Marlén Ivón Castellanos Fernández62, Gabriela Castillo-Lopez63, Graciela Castro‐Narro64, Henry Lik‐Yuen Chan65, Wah‐Kheong Chan66, Yoosoo Chang67, Massimo Colombo68, Kirsten J. Coppell69, Kathleen E. Corey70, Antonio Craxı̀71, Donna R. Cryer72, Anuradha Supun Dassanayake73, Antonieta de Ascenção Soares Martins74, Victor de Lédinghen75, Stefano DelPrato76, Alessandro Demaio77, Hailemichael Desalegn78, John Dillon79, Ajay Duseja80, Dorairaj Prabhakaran81, Mattias Ekstedt82, Moham ed El Kassas83, Osama Mohamed Elsanousi84, Gamal Esmat85, Jian‐Gao Fan86, Nathalie J. Farpour‐Lambert87, Robert Flisiak88, Yasser Fouad89, Michael Fuchs90, Rino Alvani Gani91, Lynn H. Gerber92, Hasmik Ghazinyan93, Liana Gheorghe94, George Boon‐Bee Goh95, Henning Grønbæk96, Aghayeva Gulnara97, Saeed Hamid98, Vanessa Hebditch99, Ingrid J. Hickman100, Samantha Hocking101, Béla Hunyady102, Ramazan Idılman103, Isakov Va104, Mohammad H. Jamal105, Peter Jepsen96, Natacha Jreige Iskandar106, Myeong Jun Song107, K. C. Sudhamshu108, Satoru Kakizaki109, George Kalamitsis110, Fasiha Kanwal111, Jia‐Horng Kao112, Lee M. Kaplan70, Takumi Kawaguchi113, Yousef Khader114, Seung Up Kim115, Nicolas Kodjoh116, Ger H. Koek117, Kazuhiko Koike118, Narcisse Komas119, Mark Thursz120, Marcelo Kugelmas121, A. Labidi122, Naomi F. Lange123, Joel E. Lavine124, Mariana Lazo125, Nancy Y. Lee126, Cosmas Rinaldi Adithya Lesmana91, Chun‐Jen Liu112, Michelle T. Long127, Patricio López‐Jaramillo128, Reza Malekzadeh129, Mamun Al Mahtab130, Giulio Marchesini131, Rui Tato Marinho132, S Vázquez133, Lyudmila Mateva134, Charles Mbendi Nlombi135, P. Mélin136, Ivana Mikolašević137, Tamara Alempijević138, Carla Musso139, Atsushi Nakajima140, Edna J. Nava‐González141, Alexander Nersesov142, Dafina Nikolova143, Suzanne Norris144, Katarina Novak145, Jude A. Oben146, Janus P. Ong147, Charles Onyekwere148, George Papatheodoridis149, Imran Paruk150, Keyur Patel151, Maria Paula Macedo152, Carlos Penha‐Gonçalves153, M Figueroa154, Wolf Peter Hofmann155, Salvatore Petta71, Cláudia P. Oliveira156, Puneet Puri90, Calvin Q. Pan157, Marek Rác158, Johanna Ralston159, Alnoor Ramji160, Homie Razavi161, Marcelo Silva162, Stuart K. Roberts163, Michael Trauner164, Tamsin Rose165, Samir Rouabhia166, Patrizia Rovere–Querini167, Ian Rowe168, Shakhlo Sadirova48, Riina Salupere169, Tobokalova Saparbu170, Raymond Sayegh171, Giada Sebastiani172, Yosuke Seki173, Josefina Selmo174, Abdel Karim Sermé175, Jonathan E. Shaw176, K T Shenoy177, Nick Sheron178, Oren Shibolet179, Ігор Миколайович Скрипник180, Piotr Socha181, Joan B. Soriano182, C. Wendy Spearman183, Kannan Sridharan184, Juan José Suárez185, Dhastagir Sultan Sheriff186, Ki‐Chul Sung187, Mark G. Swain188, Frank Tacke189, Shahrad Taheri190, Soek-Siam Tan191, Elliot B. Tapper192, Hannele Yki‐Järvinen193, Maja Thiele194, Isaac Thom Shawa195, Ieva Tolmane196, Esther A. Torres197, Sombat Treeprasertsuk198, Adela Turcanu199, Jonas Valantinas200, Mette Vesterhus201, Imam Waked202, Sarah H. Wild203, J. Willemse204, Robert J. Wong205, Stavra A. Xanthakos206, Dan Yock Young207, Ming‐Lung Yu208, Kenneth I. Zheng209, Mudjat Zeybel210, Ming‐Hua Zheng209
1Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
2EASL International Liver Foundation, Geneva, Switzerland
3Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
4Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile
5Centre for Obesity Research, University College London and National Institute of Health Research, UCLH Biomedical Research Centre, London, UK
6Department of Hepatology, Hôpital Beaujon, Université de Paris, Paris, France
7Clínica Universitária de Gastrenterologia, Laboratório de Nutrição, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
8Gastroenterology and Heptology Unit, Hospital Universitario Marqués de Valdecilla, Santander, IDIVAL, Santander, Spain
9Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Veterans Health Administration and University of Florida, Gainesville, FL, USA
10Department of Health Metrics Sciences, Department of Family Medicine, University of Washington, Seattle, WA, USA
11Department of Gastroenterology Hepatology, University Hospital Antwerp, Antwerp, Belgium
12Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia
13Department of Medicine, Karolinska Institutet, Stockholm, Sweden
14Center for Systems and Community Design and NYU-CUNY Prevention Research Center, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA
15Division of Gastroenterology, Department of Internal Medicine, King Fahd Hospital of the University, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
16Kautz5, Köln, Germany
17Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
18Department of Medicine, NAFLD Research Center, La Jolla, CA, USA
19University of California Berkeley, School of Public Health, Forum for Collaborative Research, Washington, DC, USA
20National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK
21Hepatitis Education Project, Seattle, WA, USA
22Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda
23Assistance Publique-Hôpitaux de Paris, Hôpital Pitie-Salpetriere, University of Paris, Paris, France
24Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
25Department of Community Health and Social Sciences, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA
26UCM Digestive Diseases, CIBEREHD, and IBIS, Virgen del Rocío University Hospital, University of Seville, Seville, Spain
27Metabolic Liver Research Program, I. Department of Medicine, University Medical Centre Mainz, Mainz, Germany
28University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, UK
29Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
30Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
31Department of Gastroenterology, Marmara University School of Medicine, Istanbul, Turkey
32Center for Liver Diseases, Inova Medicine, Falls Church, VA, USA
33University of Haifa, Faculty of Social Welfare and Health Sciences, School of Public Health, Mount Carmel, Haifa, Israel
34Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland
35University of Western Australia, Perth, Western Australia, Australia
36Ibrahim Bin Hamad Obaid Allah Hospital, Ras al Khaimah, United Arab Emirates
37Armed Forces Hospital, Muscat, Oman
38Association of Specialists in Gastroenterology and Digestive Endoscopy of Costa Rica, San Jose, Costa Rica
39Mayo Clinic, Rochester, NY, USA
40Imperial College London, London, UK
41Liver Transplant Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
42Liver Disease Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
43Sapienza University of Rome, Rome, Italy
44UGC Aparato Digestivo and Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga - IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain
45University of Health and Allied Sciences, Ho, Ghana
46University of KwaZulu-Natal, Durban, South Africa
47Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
48Research Institute of Virology of the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan
49UNIVERSITY OF VIRGINIA, Charlottesville, VA USA
50University of Pittsburgh, Pittsburgh, PA, USA;
51National Public Health Laboratory of Sudan and Ahfad University for Women, Khartoum, Sudan
52Diabetes Research Institute, San Raffaele Hospital and San Raffaele Vita Salute University, Milan, Italy
53Saint Joseph Hospital Marseille, Marseille, France
54General University Hospital and Charles University, Prague, Czech Republic
55Department of Medical Sciences, University of Turin, Turin, Italy
56University of Padua-Italy, Padua, Italy
57Vall d'Hebron University Hospital, Barcelona, Spain
58Southampton National Institute for Health Research Biomedical Research Centre and the Institute of Developmental Sciences, University of Southampton, Southampton, UK
59Hospital University of Puerta de Hierro, Majadahonda, Spain
60Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille, France
61University of the West Indies, Nassau, Bahamas
62Institute of Gastroenterology, Medical University of Havana, Havana, Cuba
63Buenos Aires University, Buenos Aires, Argentina
64Latin American Association for the Study of the Liver (ALEH), Mexico City, Mexico
65Union Hospital, Hong Kong, China
66Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
67Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea
68San Raffaele Hospital, Milan, Italy
69Department of Medicine, University of Otago, Dunedin, New Zealand
70Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
71University of Palermo, Palermo, Italy
72Global Liver Institute, Washington, DC, USA
73University of Kelaniaya, Colombo, Sri Lanka
74University of Cabo Verde, Praia, Cabo Verde
75Hospital Center University of Bordeaux, Bordeaux, France
76University of Pisa, Pisa, Italy
77VicHealth, Melbourne, Victoria, Australia
78St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia
79University of Dundee, Dundee, UK
80Postgraduate Institute of Medical Education and Research, Chandigarh, India
81World Heart Federation, Geneva, Switzerland
82Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
83Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
84The National Ribat University, Khartoum, Sudan
85Cairo University Hospitals, Cairo, Egypt
86Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
87European Association for the Study of Obesity (EASO), Teddington, UK
88Medical University of Bialystok, Bialystok, Poland
89Minia University, Minia, Egypt
90Virginia Commonwealth University and Central Virginia Veterans Affairs Health Systems, Richmond, VA, USA
91Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, Indonesia
92Inova Health System, Falls Church, VA, USA
93Armenian Association for the Study of the Liver (ARASL), Yerevan, Armenia
94University of Medicine and Pharmacy Carol Davila Bucharest, Romania
95Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore, Singapore
96Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
97Azerbaijan Gastroenterologists and Hepatologists Association, Baku, Azerbaijan
98Aga Khan University, Karachi, Pakistan
99British Liver Trust, Bournemouth, UK
100Princess Alexandra Hospital, Brisbane, Queensland, Australia
101Department of Endocrinology, Royal Prince Alfred Hospital and Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
102Somogy County Kaposi Mór Teaching Hospital, Kaposvár and University of Pécs, Pécs, Hungary
103Ankara University School of Medicine, Ankara, Turkey
104Department of Gastroenterology & Hepatology, Federal Research Center of Nutrition, Biotechnology & Food Safety, Moscow, Russia
105Kuwait University, Kuwait City, Kuwait
106Horacio Oduber Hospital, Oranjestad, Aruba
107Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
108National Academy of Medical Sciences, Kathmandu, Nepal
109Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan
110Liver Patients International, Athens, Greece
111Baylor College of Medicine, Houston, TX USA
112National Taiwan University Hospital, Taipei, Taiwan
113Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
114Jordan University of Science and Technology, Irbid, Jordan
115Yonsei University, Seoul, Republic of Korea
116University of Abomey Calavi, Faculty of Health Sciences, Cotonou, Benin
117Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, Netherlands
118University of Tokyo, Tokyo, Japan
119Pasteur Institute of Bangui, Bangui, Central African Republic
120European Liver Patients Association, Brussels, Belgium
121South Denver Gastroenterology, Denver, CO, USA
122Gastroenterology “A” Department, Rabta Hospital, Faculty of Medicine of Tunis, Tunis, Tunisia
123University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland
124Columbia University, New York, NY, USA
125Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA
126Wilton Park, Steyning, UK
127Boston University School of Medicine, Boston, MA, USA
128University of Santander (UDES), Bucaramanga, Colombia
129Digestive Disease Research Center, Tehran University of Medical Science, Tehran, Iran
130Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
131University of Bologna, Bologna, Italy
132Lisbon North University Hospital Center, Lisbon, Portugal
133Gastroenterology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
134University Hospital St. Ivan Rilski, Sofia, Bulgaria
135Service of Hepatogastroenterology, Department of Internal Medicine, University Clinic of Kinshasa, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
136Saint-Dizier Hospital Center, Saint Dizier, France
137University Hospital Center Rijeka, Rijeka, Croatia
138Clinical Center of Serbia, Beograd, Serbia
139Favaloro Foundation, Buenos Aires, Argentina
140Yokohama City University, Yokohama, Japan
141University of Nuevo Leon, San Nicolás de los Garza, Mexico
142Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
143University Clinic of Gastroenterohepatology, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia
144St James's Hospital, Dublin, Ireland
145University Medical Center Ljubljana, Ljubljana, Slovenia
146Guy's and St Thomas' Hospital, London, UK
147University of the Philippines College of Medicine, Manila, Philippines
148Lagos State University College of Medicine, Lagos, Nigeria
149National and Kapodistrian University of Athens, Athens, Greece
150University of KwaZulu Natal, Durban, South Africa
151University Health Network Toronto, Toronto, Ontario, Canada
152Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School-FCM, Universidade Nova de Lisboa, Lisboa, Portugal
153Instituto Gulbenian de Ciencia, Oeiras, Portugal
154Dominican Society of Gastroenterology, Santo Domingo, Dominican Republic
155Gastroenterology at Bayerischer Platz, Berlin, Germany
156University of Sao Paulo School of Medicine, Sao Paulo, Brazil
157NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA
158Teaching Hospital Nitra, Nitra, Slovakia
159World Obesity Federation, London, UK
160University of British Columbia, Vancouver, British Columbia, Canada
161Center for Disease Analysis Foundation, Lafayette, LA, USA
162School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
163Alfred Health, Melbourne, Victoria, Australia
164Department of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich-Heine University, Düsseldorf, Germany
165Friends of Europe, Brussels, Belgium
166University Hospital Touhami Benflis, Batna, Algeria
167IRCCS San Raffaele Hospital and University, Milan, Italy
168University of Leeds, Leeds, UK
169University of Tartu, Tartu University Hospital, Tartu, Estonia
170Kyrgyz State Medical Institute for Advanced Training and Retraining, Bishkek, Kyrgyz Republic
171Hotel Dieu de France and St Joseph University School of Medicine, Beirut, Lebanon
172McGill University Health Centre, Montreal, Quebec, Canada
173Weight Loss and Metabolic Surgery Center, Yotsuya Medical Cube, Tokyo, Japan
174Ciudad Sanitaria Dr. Luis E. Aybar, Santo Domingo, Dominican Republic
175University of Ouagadougou, Ouagadougou, Burkina Faso
176Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
177Sree Gokulam Medical College, Venjarammoodu, Kerala, India
178Kings College London, London, UK
179Tel-Aviv Medical Centre and Tel-Aviv University, Tel-Aviv, Israel
180Poltava State Medical University, Poltava, Ukraine
181The Children’s Memorial Health Institute, Warsaw, Poland
182La Princesa University Hospital, Madrid, Spain
183Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
184Department of Pharmacology & Therapeutics, College of Medicine & Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain
185Universidad San Francisco de Quito, Medicine School, Quito, Ecuador
186Anna Medical College, Monte Blanche, Mauritius
187Kangbuk Samsung Hospital, Sungkunkwan University, Seoul, Republic of Korea
188University of Calgary, calgary, Alberta, canada
189Charité – Universitätsmedizin Berlin, Berlin, Germany
190Weill Cornell Medicine Qatar, Ar-Rayyan, Qatar
191Selayang Hospital, Batu Caves, Malaysia
192University of Michigan, Ann Arbor, MI USA
193Helsinki University Hospital, Helsinki, Finland
194Odense University Hospital, Odense, Denmark
195University of Malawi, College of Medicine, Blantyre, Malawi
196Riga East University Hospital, Riga, Latvia
197University of Puerto Rico School of Medicine, San Juan, Puerto Rico.
198King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand
199Gastroenterology, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chișinău, Republic of Moldova
200Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania
201Haraldsplass Deaconess Hospital and University of Bergen, Bergen, Norway
202National Liver Institute, Shibin Al Kawm, Egypt
203Usher Institute, University of Edinburgh, Edinburgh, UK
204Dutch Liver Patients Association, Hoogland, Netherlands
205Stanford University School of Medicine, Stanford, CA, USA
206Cincinnati Children’s Hospital Medical Center, Cincinnati, OH USA
207National University Singapore, Singapore
208Hepatobiliary Section, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
209NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
210Koç Üniversitesi, Istanbul, Turkey

Tóm tắt

Từ khóa


Tài liệu tham khảo

Golabi, P. et al. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL). Health Qual. Life Outcomes 14, 18 (2016).

McSweeney, L. et al. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Rep. 2, 100099 (2020).

O’Hara, J. et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2, 100142 (2020).

Schattenberg, J. M. et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in five European countries in 2018: a cost-of-illness analysis. Liver Int. 41, 1227–1242 (2021).

Younossi, Z. M. et al. The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Gastroenterology https://doi.org/10.1053/j.gastro.2020.12.003 (2020).

Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586 (2016).

Hagström, H. et al. Health care costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls. Clin. Gastroenterol. Hepatol. 18, 1592–1599.e8 (2020).

Gordon, S. C., Fraysse, J., Li, S., Ozbay, A. B. & Wong, R. J. Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis Medicare patients. Am. J. Gastroenterol. 115, 562–574 (2020).

Bertot, L. C. & Adams, L. A. The natural course of non-alcoholic fatty liver disease. Int. J. Mol. Sci. 17, 774 (2016).

Ekstedt, M., Nasr, P. & Kechagias, S. Natural history of NAFLD/NASH. Curr. Hepatol. Rep. 16, 391–397 (2017).

Araújo, A. R., Rosso, N., Bedogni, G., Tiribelli, C. & Bellentani, S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 38, 47–51 (2018).

Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155, 1828–1837.e2 (2018).

Haldar, D. et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study. J. Hepatol. 71, 313–322 (2019).

Terrault, N. A. & Pageaux, G.-P. A changing landscape of liver transplantation: king HCV is dethroned, ALD and NAFLD take over! J. Hepatol. 69, 767–768 (2018).

Global Burden of Disease Cancer Collaboration et al.Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 5, 1749–1768 (2019).

Adams, L. A., Anstee, Q. M., Tilg, H. & Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138–1153 (2017).

Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330–344 (2013).

Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62, S47–S64 (2015).

Albhaisi, S., Chowdhury, A. & Sanyal, A. J. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep.: Innov. Hepatol. 1, 329–341 (2019).

Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11–20 (2018).

Vilar-Gomez, E. et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 155, 443–457.e17 (2018).

Angulo, P. et al. Liver fibrosis, but no other histologic features, is asssociated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.e10 (2015).

Haflidadottir, S. et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol. 14, 166 (2014).

Park, S. K., Seo, M. H., Shin, H. C. & Ryoo, J. H. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 57, 1378–1383 (2013).

World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. WHO https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236_eng.pdf (2013).

Bennett, J. E. et al. NCD countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 392, 1072–1088 (2018).

Rotondi, A. & Gustafson, D. in Gazing into the Oracle: The Delphi Method and its Application to Social Policy and Public Health (eds Adler, M. & Ziglio, E.) 34–55 (Jessica Kingsley, 1996).

Rubino, F. et al. Joint international consensus statement for ending stigma of obesity. Nat. Med. 26, 485–497 (2020).

Lazarus, J. V. et al. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nat. Commun. 12, 4450 (2021).

Vos, T. et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).

Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).

Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J. Hepatol. 69, 896–904 (2018).

Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).

Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69, 2672–2682 (2019).

Ye, Q. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 739–752 (2020).

Bjorkstrom, K., Stal, P., Hultcrantz, R. & Hagstrom, H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 15, 1461–1468 (2017).

Musso, G., Gambino, R., Cassader, M. & Pagano, G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617–649 (2011).

Sepanlou, S. G. et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 245–266 (2020).

Anderson, E. L. et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE 10, e0140908 (2015).

Jimenez-Rivera, C. et al. Prevalence and risk factors for non-alcoholic fatty liver in children and youth with obesity. BMC Pediatr. 17, 113 (2017).

Xanthakos, S. A. et al. High prevalence of nonalcoholic fatty liver disease in adolescents undergoing bariatric surgery. Gastroenterology 149, 623–634.e8 (2015).

Yu, E. L. et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J. Pediatr. 207, 64–70 (2019).

Schwimmer, J. B. et al. Prevalence of fatty liver in children and adolescents. Pediatrics 118, 1388–1393 (2006).

Yüksel, F. et al. Fatty liver disease in an autopsy series of children and adolescents. Hippokratia 16, 61–65 (2012).

Rocha, R. et al. Nonalcoholic fatty liver disease in asymptomatic Brazilian adolescents. World J. Gastroenterol. 15, 473–477 (2009).

Zhang, X. et al. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ Open 11, e042843 (2021).

Schwimmer, J. B. et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42, 641–649 (2005).

Nobili, V. et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat. Rev. Gastroenterol. Hepatol. 16, 517–530 (2019).

Vos, M. B. et al. Factors to consider in development of drugs for pediatric nonalcoholic fatty liver disease. Gastroenterology 157, 1448–1456.e1 (2019).

Nadeau, K. J. et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care 39, 1635–1642 (2016).

Zimmermann, E. et al. Body mass index in school-aged children and the risk of routinely diagnosed non-alcoholic fatty liver disease in adulthood: a prospective study based on the Copenhagen School Health Records Register. BMJ Open 5, e006998 (2015).

Berentzen, T. L., Gamborg, M., Holst, C., Sørensen, T. I. & Baker, J. L. Body mass index in childhood and adult risk of primary liver cancer. J. Hepatol. 60, 325–330 (2014).

Hagström, H., Stål, P., Hultcrantz, R., Hemmingsson, T. & Andreasson, A. Overweight in late adolescence predicts development of severe liver disease later in life: a 39years follow-up study. J. Hepatol. 65, 363–368 (2016).

Hagström, H., Tynelius, P. & Rasmussen, F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut 67, 1536–1542 (2018).

Simon, T. G. et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J. Hepatol. https://doi.org/10.1016/j.jhep.2021.06.034 (2021).

Younossi, Z. M. et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 37, 1209–1218 (2017).

Doward, L. C. et al. Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study. Patient 14, 533–543 (2021).

Twiss, J. et al. Development of a new patient-reported outcome measure for non-alcoholic steatohepatitis: NASH-CHECK [abstract PGI39]. Value Health 20, A638 (2017).

Huber, Y. et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin. Gastroenterol. Hepatol. 17, 2085–2092.e1 (2019).

David, K. et al. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the Nonalcoholic Ateatohepatitis Clinical Research Network. Hepatology 49, 1904–1912 (2009).

Kennedy-Martin, T., Bae, J. P., Paczkowski, R. & Freeman, E. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. J. Patient Rep. Outcomes 2, 28 (2017).

Casey, J. A., Schwartz, B. S., Stewart, W. F. & Adler, N. E. Using electronic health records for population health research: a review of methods and applications. Annu. Rev. Public Health 37, 61–81 (2016).

Hagström, H. et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology https://doi.org/10.1002/hep.31726 (2021).

Sanyal, A. J. Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing? BMC Med. 16, 148 (2018).

Bergqvist, C. J. et al. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern. Med. J. 43, 247–253 (2013).

Alemany-Pagès, M. et al. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 20, 1142–1142 (2020).

Wieland, A. C. et al. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J. Clin. Gastroenterol. 49, e6–e10 (2015).

Goh, G. B. B. et al. Perceptions of non-alcoholic fatty liver disease – an Asian community-based study. Gastroenterol. Rep. 4, 131–135 (2016).

Ghevariya, V. et al. Knowing what’s out there: awareness of non-alcoholic fatty liver disease. Front. Med. 1, 4 (2014).

Augustin, S., Pons, M., Santos, B., Ventura, M. & Genescà, J. in Portal Hypertension VI: Proceedings of the Sixth Baveno Consensus Workshop: Stratifying Risk and Individualizing Care (ed. de Franchis, R.) 39–49 (Springer, 2016).

de Franchis, R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying Risk and Individualizing Care for Portal Hypertension. J. Hepatol. 63, 743–752 (2015).

Lazarus, J. V. et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J. Intern. Med. 286, 503–525 (2019).

Lazarus, J. V. et al. Defining comprehensive models of care for NAFLD. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-021-00477-7 (2021).

Grgurevic, I. et al. Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach. Can. J. Gastroenterol. Hepatol. 2020, 9181368 (2020).

Dyson, J. K., Anstee, Q. M. & McPherson, S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 5, 277–286 (2014).

Ruissen, M. M., Mak, A. L., Beuers, U., Tushuizen, M. E. & Holleboom, A. G. Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease. Eur. J. Endocrinol. 183, R57–R73 (2020).

Ahmed, M. H., Woodward, C. & Mital, D. Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services. Cardiovasc. Endocrinol. 6, 109–112 (2017).

Armstrong, M. J. et al. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM 107, 33–41 (2014).

DeVore, S. et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J. Pediatr. Gastroenterol. Nutr. 57, 119–123 (2013).

Moolla, A. et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 10, 337–346 (2019).

Neilson, L. J. et al. Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. Frontline Gastroenterol. https://doi.org/10.1136/flgastro-2020-101480 (2021).

Dyson, J. K., Anstee, Q. M. & McPherson, S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Front. Gastroenterol. 5, 211–218 (2014).

Chalmers, J. et al. The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Front. Gastroenterol. 11, 86–92 (2020).

Dillon, J. F. et al. Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care. J. Hepatol. 71, 699–706 (2019).

Hudson, M. & McPherson, S, on behalf of the North East & North Cumbria Hepatology Network. Liver Network: Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities (Northern England Clinical Strategic Networks, 2020).

Shaheen, A. A. et al. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 8, E370–E376 (2020).

Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J. Hepatol. 71, 371–378 (2019).

Crossan, C. et al. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis. Liver Int. 39, 2052–2060 (2019).

Srivastava, A. et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol. 19, 122 (2019).

Tanajewski, L. et al. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open 7, e015659 (2017).

Alexander, M. et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 16, 130 (2018).

Cooke, G. S. et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 4, 135–184 (2019).

Mencin, A. A., Loomba, R. & Lavine, J. E. Caring for children with NAFLD and navigating their care into adulthood. Nat. Rev. Gastroenterol. Hepatol. 12, 617–628 (2015).

Taylor, R. S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 158, 1611–1625.e12 (2020).

Castera, L., Friedrich-Rust, M. & Loomba, R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1264–1281.e4 (2019).

Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J. Hepatol. 73, 252–262 (2020).

McPherson, S. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am. J. Gastroenterol. 112, 740–751 (2017).

Anstee, Q. M. et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology 70, 1521–1530 (2019).

Augustin, S. et al. Identification of patients with advanced fibrosis due to nonalcoholic fatty liver disease: considerations for best practice. J. Gastrointestin Liver Dis. 29, 235–245 (2020).

Castera, L. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: non-invasive tests are enough. Liver Int. 38(Suppl 1), 67–70 (2018).

Majumdar, A., Campos, S., Gurusamy, K., Pinzani, M. & Tsochatzis, E. A. Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis: a decision analytic modeling study. Hepatology 71, 627–642 (2020).

Jung, J. et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 70, 1946–1953 (2021).

Mosca, A., Panera, N., Crudele, A. & Alisi, A. Noninvasive diagnostic tools for pediatric NAFLD: where are we now? Expert Rev. Gastroenterol. Hepatol. 14, 1035–1046 (2020).

Di Cesare, M. et al. Inequalities in non-communicable diseases and effective responses. Lancet 381, 585–597 (2013).

Peters, R. et al. Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction. Ther. Adv. Chronic Dis. 10, 2040622319880392–2040622319880392 (2019).

Fuchs, S., Henschke, C., Blümel, M. & Busse, R. Disease management programs for type 2 diabetes in Germany: a systematic literature review evaluating effectiveness. Dtsch. Arztebl Int. 111, 453–463 (2014).

World Health Organization. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. WHO https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care (2020).

Dixon, B. E., Embi, P. J. & Haggstrom, D. A. Information technologies that facilitate care coordination: provider and patient perspectives. Transl. Behav. Med. 8, 522–525 (2018).

Ando, Y. & Jou, J. H. Nonalcoholic fatty liver disease and recent guideline updates. Clin. Liver Dis. 17, 23–28 (2021).

Leoni, S. et al. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J. Gastroenterol. 24, 3361–3373 (2018).

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).

Arab, J. P. et al. Latin American Association for the Study of the Liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann. Hepatol. 19, 674–690 (2020).

Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).

Chitturi, S. et al. The Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017–Part 2: Management and special groups. J. Gastroenterol. Hepatol. 33, 86–98 (2018).

Eslam, M. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. 14, 889–919 (2020).

Muthiah, M. D. & Sanyal, A. J. Current management of non-alcoholic steatohepatitis. Liver Int. 40 (Suppl. 1), 89–95 (2020).

Hallsworth, K. & Adams, L. A. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep. Innov. Hepatol. 1, 468–479 (2019).

Romero-Gómez, M., Zelber-Sagi, S. & Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 67, 829–846 (2017).

Jensen, M. D. et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129, S102–S138 (2014).

Hydes, T. J., Ravi, S., Loomba, R. & Gray, M. E. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin. Mol. Hepatol. 26, 383–400 (2020).

Geurtsen, M. L., Santos, S., Gaillard, R., Felix, J. F. & Jaddoe, V. W. V. Associations between intake of sugar-containing beverages in infancy with liver fat accumulation at school age. Hepatology 73, 560–570 (2021).

Berná, G. & Romero-Gomez, M. The role of nutrition in non-alcoholic fatty liver disease: pathophysiology and management. Liver Int. 40 (Suppl. 1), 102–108 (2020).

Hashida, R. et al. Aerobic vs resistance exercise in non-alcoholic fatty liver disease: a systematic review. J. Hepatol. 66, 142–152 (2017).

Lazarus, J. V. et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J. Hepatol. 72, 14–24 (2020).

Neuschwander-Tetri, B. A. Therapeutic landscape for NAFLD in 2020. Gastroenterology 158, 1984–1998.e3 (2020).

Wong, E. L. Y. et al. Patient experience and satisfaction with inpatient service: development of short form survey instrument measuring the core aspect of inpatient experience. PLoS ONE 10, e0122299 (2015).

Martin, L. R., Williams, S. L., Haskard, K. B. & Dimatteo, M. R. The challenge of patient adherence. Ther. Clin. Risk Manag. 1, 189–199 (2005).

World Health Assembly. Hepatitis. WHO https://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf?ua=1 (2014).

Puhl, R. M. & Heuer, C. A. Obesity stigma: important considerations for public health. Am. J. Public Health 100, 1019–1028 (2010).

Room, R. Stigma, social inequality and alcohol and drug use. Drug Alcohol. Rev. 24, 143–155 (2005).

Vaughn-Sandler, V., Sherman, C., Aronsohn, A. & Volk, M. L. Consequences of perceived stigma among patients with cirrhosis. Dig. Dis. Sci. 59, 681–686 (2014).

Himmelstein, M. S. & Puhl, R. M. At multiple fronts: diabetes stigma and weight stigma in adults with type 2 diabetes. Diabet. Med. 38, e14387 (2021).

Lazarus, J. V. et al. European ‘NAFLD Preparedness Index’–is Europe ready to meet the challenge of fatty liver disease? JHEP Rep. 3, 100234 (2021).

Lazarus, J. V. et al. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge? Int. Liver Congr. 75 (Suppl. 2), 23–26 (2021).

NASH Council & Global Liver Institute. U.S NASH action plan (Global Liver Institute, 2020).

World Health Organization. Continuity and coordination of care: a practice brief to support implementation of the WHO Framework on integrated people-centred health services (Alliance for Health Policy and Systems Research, 2018).

Atun, R. et al. Improving responsiveness of health systems to non-communicable diseases. Lancet 381, 690–697 (2013).

Rutter, H. et al. The need for a complex systems model of evidence for public health. Lancet 390, 2602–2604 (2017).

Kumanyika, S., Jeffery, R. W., Morabia, A., Ritenbaugh, C. & Antipatis, V. J. Obesity prevention: the case for action. Int. J. Obes. Relat. Metab. Disord. 26, 425–436 (2002).

Gortmaker, S. L. et al. Changing the future of obesity: science, policy, and action. Lancet 378, 838–847 (2011).

Huang, T. T., Drewnosksi, A., Kumanyika, S. & Glass, T. A. A systems-oriented multilevel framework for addressing obesity in the 21st century. Prev. Chronic Dis. 6, A82 (2009).

Huang, T. & Ferris, E. in Childhood Obesity Ch. 42 (ed. Goran, M. I.) (Taylor and Francis, 2016).

Huang, T. T. et al. Mobilisation of public support for policy actions to prevent obesity. Lancet 385, 2422–2431 (2015).

Lazarus, J. V. et al. A Sustainable Development Goal framework to guide multisectoral action on NAFLD through a societal approach. Preprint at medRxiv https://doi.org/10.1101/2021.08.02.21261464 (2021).

Adler, M. & Ziglio, E. Gazing into the Oracle: The Delphi Method and its Application to Social Policy and Public Health (Jessica Kingsley, 1996).

Grime, M. M. & Wright, G. in Wiley StatsRef: Statistics Reference Online 1–6 (Wiley, 2011).

Targher, G. & Byrne, C. D. From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: is it time for a change of terminology? Hepatoma Res. 6, 64 (2020).

Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 73, 202–209 (2020).

Eslam, M., Sanyal, A. J. & George, J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999–2014.e1 (2020).

Mendez-Sanchez, N. et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol. Hepatol. 6, 65–72 (2021).

Spearman, C. W. et al. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD. J. Hepatol. 74, 1256–1258 (2021).

Shiha, G. et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol. Hepatol. 6, 57–64 (2021).

Ratziu, V. et al. The times they are a-changin’ (for NAFLD as well). J. Hepatol. 73, 1307–1309 (2020).

Younossi, Z. M. et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 73, 1194–1198 (2021).

Wong, V. W. et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017–Part 1: definition, risk factors and assessment. J. Gastroenterol. Hepatol. 33, 70–85 (2018).

American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes — 2020. Diabetes Care 43, S37–S47 (2020).

World Health Organization. Nothing for us, without us: opportunities for meaningful engagement of people living with NCDs: meeting report (WHO, 2021).